Georgina V. Long

Oncology · 2011–2022

A researcher in the Science corpus: 39 papers; trusts 1 researcher and is trusted by 0 researchers here, as inferred from the citation graph.

Subfields

• Oncology — 322 citations into it

Whom Georgina V. Long trusts overall

Their strongest outbound trust, strongest first, inferred from their citations.

1. C. Robert
2. K. Flaherty

Papers from Georgina V. Long's perspective

Ordered by how strongly the researchers Georgina V. Long trusts endorse each paper. Same corpus, a different order for every researcher.

1. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. (New England Journal of Medicine)
2. Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma (New England Journal of Medicine)
3. Nivolumab versus Everolimus in Advanced Renal Cell Carcinoma (New England Journal of Medicine)
4. Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer (New England Journal of Medicine)
5. Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer (New England Journal of Medicine)
6. PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma (New England Journal of Medicine)
7. Two-year overall survival rates from a randomised phase 2 trial evaluating the combination of nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma (The Lancet Oncology)
8. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. (The Lancet)
9. Signatures of mutational processes in human cancer (Nature)
10. Final Trial Report of Sentinel-Node Biopsy versus Nodal Observation in Melanoma (New England Journal of Medicine)

Their papers

• Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients (2018) — 792 citations
• Comprehensive Characterization of Cancer Driver Genes and Mutations (2018) — 2,007 citations
• Combined Nivolumab and Ipilimumab or Monotherapy in Previously Untreated Melanoma (2015) — 4,132 citations
• Combined BRAF and MEK Inhibition in Melanoma with BRAF V600 Mutations (2012) — 2,686 citations
• Selective BRAF Inhibitors Induce Marked T-cell Infiltration into Human Metastatic Melanoma (2011) — 631 citations
• Improved overall survival in melanoma with combined dabrafenib and trametinib. (2015) — 2,453 citations
• Genomic Classification of Cutaneous Melanoma (2015) — 2,764 citations
• Pembrolizumab versus Ipilimumab in Advanced Melanoma. (2015) — 5,305 citations
• Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy (2013) — 925 citations
• Melanoma whole exome sequencing identifies V600EB-RAF amplification-mediated acquired B-RAF inhibitor resistance (2012) — 643 citations
• Nivolumab in previously untreated melanoma without BRAF mutation. (2015) — 5,260 citations
• Whole-genome landscapes of major melanoma subtypes (2017) — 1,278 citations
• Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma (2017) — 3,400 citations
• Safety Profile of Nivolumab Monotherapy: A Pooled Analysis of Patients With Advanced Melanoma. (2017) — 985 citations
• Targeted agents and immunotherapies: optimizing outcomes in melanoma (2017) — 1,125 citations
• Melanoma Staging: Evidence-Based Changes in the American Joint Committee on Cancer Eighth Edition Cancer Staging Manual (2017) — 2,184 citations
• Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. (2019) — 933 citations
• Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma. (2019) — 1,148 citations
• Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. (2019) — 2,934 citations
• Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. (2011) — 1,048 citations